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Abstract 
Background: It is uncertain whether non‑alcoholic fatty liver disease (NAFLD) or abdominal obesity is more asso‑
ciated with atherosclerosis. The aim of this study was to determine whether NAFLD or abdominal obesity is more 
strongly associated with subclinical atherosclerosis represented by coronary artery calcification (CAC).
Methods: A total of 21,335 male participants in a health screening program (mean age 41 years) were enrolled. Ultra‑
sonographic measurements of fatty liver and multi‑detector computed tomography were performed to determine 
the coronary artery calcium score (CACS). The presence of CAC was defined as CACS >0. Subjects were divided into 
four groups according to the presence or absence of NAFLD and/or abdominal obesity as assessed by waist‑hip ratio 
(WHR) >0.9.
Results: The presence of CAC was detected in 2,385 subjects (11.2%). The proportion of subjects with CAC was high‑
est in the abdominal obesity only group (23.2%). After adjustment for age, diabetes history, hypertension, cigarette 
smoking, and physical inactivity, the odds ratio (OR) for CAC was the highest in the group with both abnormalities 
[1.465 (1.324–1.623)]. The NAFLD only group showed significantly increased OR for CAC compared to that in the 
abdominal obesity only group [1.286 (1.151–1.436) vs. 1.076 (0.939–1.233)].
Conclusion: Non‑alcoholic fatty liver disease is more closely associated with CAC than abdominal obesity as 
assessed by the WHR. NAFLD could be considered an independent determinant of subclinical atherosclerosis as 
assessed by CAC.
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Background
Coronary artery disease (CAD) due to atherosclerosis is a 
leading cause of morbidity and mortality worldwide and 
continues to be a significant health problem and global 
burden [1]. Early detection of subclinical atherosclerosis 
is necessary to prevent progression towards overt CAD. 
Obesity is considered an independent risk factor for ath-
erosclerosis and CAD [2, 3], and is also associated with 
other CAD risk factors including hypertension, diabetes, 
and dyslipidemia [4, 5]. Recent studies have concentrated 
on the localized distribution of body fat rather than over-
all obesity, and abdominal obesity has thus been indi-
cated as a strong risk factor for CAD [6, 7].
Non-alcoholic fatty liver disease (NAFLD) has become 
an emerging public health concern that parallels the rise 
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in metabolic syndrome and obesity [8, 9]. NAFLD is now 
recognized as the hepatic manifestation of metabolic 
syndrome and insulin resistance (IR) [8]. Recent stud-
ies suggest that NAFLD contributes to the development 
of subclinical atherosclerosis or cardiovascular disease 
and could be considered as a cardiovascular risk factor 
[10–13]. The risk assessment of NAFLD and abdomi-
nal obesity is clinically important for the application of 
both lifestyle and/or pharmacological therapies targeted 
to lower atherosclerosis. However, it is unclear whether 
NAFLD or abdominal obesity is more strongly associated 
with atherosclerosis.
Early detection of subclinical atherosclerosis is 
important to prevent overt CAD, and coronary artery 
calcification (CAC) is a useful marker of subclini-
cal atherosclerosis [14]. CAC score (CACS) reflects 
the general cardiovascular burden of the arteries in 
our body as it correlates well with the atheromatous 
plaque burden in autopsy studies [15]. CAC scoring 
with multi-detector computed tomography (MDCT) 
is a useful and non-invasive tool for risk prediction of 
subclinical atherosclerosis in asymptomatic individuals 
and also correlated well with cardiovascular events and 
obesity [16].
Recent studies suggest the association of NAFLD with 
subclinical atherosclerosis assessed by CACS [17–23]. 
The aim of the present study was to determine whether 
NAFLD or abdominal obesity is more associated with 
subclinical atherosclerosis in apparently healthy Korean 
men. To answer this question, we assessed the risk of 
CAC in subjects divided into four groups according to 
the presence/absence of NAFLD as diagnosed by ultra-
sonography and presence/absence of abdominal obesity 
measured by the waist-hip ratio (WHR) status. We ana-
lyzed CAC in these groups to clarify whether NAFLD or 
abdominal obesity is associated with CAC.
Methods
Study design and study population
This cross-sectional retrospective study was a part of 
the Kangbuk Samsung Health Study, in which subjects 
participated in a medical health check program at the 
Health Promotion Center of Kangbuk Samsung Hospi-
tal, Sungkyunkwan University, Seoul, Korea. The purpose 
of this medical health check program was to promote 
the health of employees through regular checkups and 
to enhance early detection of existing diseases. Health 
checks included blood tests, anthropometry, and abdom-
inal ultrasonography examination, and in some cases, the 
health checks included CAC scoring by MDCT. The CAC 
test is offered as part of the routine health check program 
and therefore there is no medical indication for perform-
ing the test.
Ultrasonography measurements of fatty liver and 
MDCT for CAC scoring were performed in 26,857 men 
in the medical checkup program between January 2010 
and December 2011. We excluded subjects who had a 
self-reported history of heart attack and CAD includ-
ing acute myocardial infarction, angina, or congestive 
heart failure; subjects who reported a daily alcohol intake 
≥20 g; subjects having serologic evidence of viral hepa-
titis or other chronic liver disease; and subjects with any 
missing data. A total of 21,335 men were selected for 
analysis.
Anthropometric and laboratory measurements
Blood pressure was measured using a standardized 
sphygmomanometer after 5 min of rest, according to the 
Hypertension Detection and Follow-up Program pro-
tocol [24]. Height and weight were measured twice and 
then averaged. The BMI was calculated by dividing the 
weight (kg) by the square of the height (m). The waist cir-
cumference (WC) was measured in the standing position 
at the levels of the umbilicus.
All subjects were examined after a 12-h overnight fast. 
We analyzed blood samples for aspartate aminotrans-
ferase, alanine aminotransferase, gamma-glutamyl trans-
peptidase, total serum cholesterol, serum triglycerides, 
serum high-density lipoprotein cholesterol, low density 
lipoprotein cholesterol, fasting blood glucose level, serum 
high-sensitivity C-reactive protein (hs-CRP), serum insu-
lin level, and glycated hemoglobin A1c (HbA1c). Bio-
chemical markers were measured using Bayer Reagent 
Packs on an automated chemistry analyzer (ADVIA 
1650 Autoanalyzer; Bayer HealthCare, Tarrytown, NY, 
USA). Lipid profiles were measured via enzymatic col-
orimetric assay. Fasting blood glucose levels were meas-
ured using the hexokinase method. Serum hs-CRP levels 
were measured using a nephelometric assay with a BNII 
nephelometer (Dade Behring, Deerfield, IL, USA). Insu-
lin resistance was measured using the homeostatic model 
for the assessment index-insulin resistance (HOMA-IR) 
and was obtained by applying the following formula: 
HOMA-IR  =  fasting insulin (IU/mL)  ×  fasting blood 
glucose (mmol/L)/22.5 [25]. HbA1c was measured using 
the immunoturbidimetric assay with a Cobra Integra 800 
automatic analyzer (Roche Diagnostics, Basel, Switzer-
land) with a reference value of 4.4–6.4% [26].
The presence of diabetes mellitus was determined from 
answers in the self-questionnaire and using the diag-
nostic criteria of the American Diabetes Association 
[27]. The presence of hypertension was defined as blood 
pressure (BP) ≥140/90 mm Hg or presently taking anti-
hypertensive medication, according to the criteria rec-
ommended by the seventh report of the Joint National 
Committee on prevention, detection, evaluation, and 
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treatment of high BP [28]. Smoking status was deter-
mined using the questionnaire. A smoker was defined as 
a subject who had ever smoked at least five packs of ciga-
rettes in his life. Exercising was defined as regular exer-
cise of moderate intensity every week.
Measurement of coronary artery calcium score
MDCT for coronary calcium scoring was undertaken 
using a 64-slice, spiral computed tomography scan (GE 
Health Care, Tokyo, Japan). CACS were expressed in 
Agaston units and the presence of CAC was defined by 
CACS >0 [29].
Diagnosis of NAFLD and abdominal obesity
Abdominal ultrasonography (ASPEN; Acuson, Pennsyl-
vania, USA) was performed by one of three radiologists 
using a 3.5 MHz probe to evaluate the presence of hepatic 
steatosis in all subjects. The diagnosis of fatty liver was 
made based on the following criteria [30, 31]: a diffuse 
hyperechoic echotexture, hepatorenal echo contrast in 
reference to the cortex of the right kidney, and vascular 
blurring and deep-echo attenuation. When making the 
diagnosis of NAFLD, the results of the liver function test 
were not taken into consideration and liver tissue was not 
examined.
Body composition measurements were carried out 
by segmental bioelectric impedance, using eight tactile 
electrodes according to the manufacturer’s instructions 
(InBody 3.0, Biospace Co. Ltd, Seoul, Korea). Lean mass 
(kg), fat mass (kg), percent fat mass (%), and WHR as a 
marker of abdominal obesity, were measured. Abdominal 
obesity, known clinically as central obesity, was assessed 
by WHR >0.90 for men using the measurement of body 
composition [32].
Ethics
The participants provided written informed consent for 
the use of their health screening data for this research. 
The design, protocol, and consent procedure of this study 
were reviewed and approved by the Institutional Review 
Board (IRB) of Kangbuk Samsung Hospital and are in 
accordance with the Helsinki Declaration of 1975. After 
the review and acceptance of the study protocol by the 
IRB, a specific dataset for this study was released to the 
data management group of the KSHS after deleting the 
personal information of the participants.
Statistical analysis
All data are presented as mean  ±  standard deviation, 
median (interquartile range) or percentage and were 
analyzed using IBM SPSS version 18.0 (IBM, Armonk, 
NY, USA). We divided subjects into four groups accord-
ing to individual NAFLD and abdominal obesity status. 
Comparison of continuous variables between the groups 
was performed by one-way analysis of variance test and 
post hoc analyses with the Tukey’s b method. Nonpara-
metric comparisons of the medians between the groups 
were performed using Kruskal–Wallis H test and Mann–
Whitney U test for post hoc analyses with Bonferroni 
correction. We used Chi square tests for the categorical 
variables. Analysis of covariance test was used to adjust 
for age.
As CACS values were extremely skewed, logarithmized 
CACS + 1 was used for the comparison of between the 
groups. CACSs were dichotomized as presence of CACS 
>0 versus absence of CACS = 0 for binary logistic regres-
sion analysis. Multivariate logistic regression analyses 
were performed to assess the association between groups 
with CAC (CACS >0) while controlling for potential con-
founding variables included in the model. Covariates in 
the multivariable model, chosen for clinical importance 
as well as statistical significance included age, diabetes, 
hypertension, cigarette smoking, and physical inactiv-
ity. Asymptomatic significances (two-sided tests) are 
reported. Significance was defined as p  <  0.05. Odds 
ratios (ORs) and 95% confidence intervals (CIs) were 
obtained.
Results
General characteristics of the participants
A total of 21,335 men (mean age 41  years; range 
23–88  years) were divided into four groups according 
to the presence or absence of NAFLD and/or abdominal 
obesity as assessed by the WHR (Table 1) as follows: (1) 
subjects without either abnormality (n =  9,052; 42.4%); 
(2) subjects with abdominal obesity only (n  =  2,220; 
10.4%); (3) subjects with NAFLD only (n = 4,859; 22.8%); 
and (4) subjects with both abnormalities (n  =  5,204; 
24.5%).
Comparison of parameters between the groups according 
to NAFLD and abdominal obesity status
Comparison of parameters between groups revealed that 
the abdominal obesity only group was the oldest, and 
the group with both abnormalities had the worst meta-
bolic parameters (Table  1). The metabolic parameters, 
with the exception of blood pressure, of the NAFLD only 
group were worse than those of the abdominal obesity 
only group. The mean WHR value of total population 
was 0.91, and subjects with NAFLD were generally more 
obese with higher mean WHR, BMI, WC, and fat mass 
compared to those in subjects without NAFLD (Table 1). 
The group with both abnormalities had the highest pro-
portion of subjects with diabetes, hypertension, and dys-
lipidemia. The proportion of subjects with diabetes and 
dyslipidemia were higher in the NAFLD only group than 
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in abdominal only group. However, the opposite was true 
for the proportion of subjects with hypertension. In addi-
tion, subjects with NAFLD tended to smoke more and 
exercise less than subjects without NAFLD (Table 1).
Comparison of coronary artery calcium score among the 
four groups divided by non‑alcoholic fatty liver disease 
and abdominal obesity status
15.9% of total population had CACS >0 and mean Ln 
(CACS + 1) was 0.49 (Table 2). While the mean value 
of CACS was the highest in the abdominal obesity 
only group and the lowest in the group without either 
abnormality, the age-adjusted mean value of CACS 
was the highest in the group with both abnormalities 
(Table  2; Figure  1). When mean Ln (CACS  +  1) was 
compared among the groups, the mean Ln (CACS + 1) 
values was the highest in the abdominal obesity 
only group and the lowest in the NAFLD only group 
(Table  2). The proportion of subjects with CAC was 
the highest in the abdominal obesity only group and 
the lowest in the group without either abnormality 
(23.2 vs. 11.3%).
Table 1 Baseline characteristics between the groups according to nonalcoholic fatty liver disease and abdominal obesity 
status
Values are expressed as mean ± standard deviation, median (interquartile range) or percentage.
NAFLD nonalcoholic fatty liver disease, WHR waist-hip ratio, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, FBS fasting blood glucose, 
TC total cholesterol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, ALT alanine aminotransferase, AST aspartate 
aminotransferase, HbA1c glycated hemoglobin.
a No differences between the groups with same footnotes in post hoc analyses.
Total population NAFLD (−)  
abdominal  
obesity (−)
NAFLD (−)  
abdominal  
obesity (+)
NAFLD (+)  
abdominal  
obesity (−)




N (%) 21,335 (100) 9,052 (42.4) 2,220 (10.4) 4,859 (22.8) 5,204 (24.5)
Age (year) 40.8 ± 7.3 39.5 ± 6.7a 45.1 ± 9.4 39.4 ± 5.8a 42.3 ± 7.6 <0.001
SBP (mmHg) 114.9 ± 12.0 112.3 ± 11.4 116.1 ± 12.2 115.1 ± 11.5 118.8 ± 12.1 <0.001
DBP (mmHg) 74.5 ± 9.6 72.4 ± 9.0 77.7 ± 9.7 75.7 ± 9.5 76.65 ± 9.6 <0.001
FBS (mg/dL) 99.1 ± 16.8 95.9 ± 12.4 99.2 ± 14.2a 100.0 ± 18.5a 103.8 ± 21.0 <0.001
TC (mg/dL) 203.0 ± 31.2 196.2 ± 32.7 203.9 ± 34.7 206.2 ± 35.3 211.6 ± 37.0 <0.001
TG (mg/dL) 122 (87–174) 97 (72–132) 117 (87–164) 142 (104–196) 160 (117–219) <0.001
HDL‑C (mg/dL) 51.1 ± 12.0 55.6 ± 12.5 51.5 ± 11.4 48.0 ± 10.4 45.9 ± 9.6 <0.001
LDL‑C (mg/dL) 131.4 ± 31.7 124.7 ± 29.6 132.6 ± 31.3 134.9 ± 31.8 139.2 ± 32.8 <0.001
AST (IU/L) 24.1 ± 13.3 21.3 ± 11.2 22.8 ± 10.8 24.5 ± 12.1 29.1 ± 16.7 <0.001
ALT (IU/L) 30.3 ± 23.7 22.1 ± 15.8 26.2 ± 19.6 33.6 ± 21.5 43.0 ± 31.3 <0.001
γ‑GTP (IU/L) 30 (21–48) 23 (17–34) 31 (21–49) 33 (24–51) 43 (30–66) <0.001
hs‑CRP (mg/dL) 0.05 (0.03–0.11) 0.04 (0.02–0.07) 0.06 (0.04–0.11)a 0.06 (0.04–0.10)a 0.09 (0.05–0.16) <0.001
HOMA‑IR 1.33 (0.877–2.000) 0.982 (0.657–1.406) 1.368 (0.931–1.959) 1.506 (1.049–2.112) 2.045 (1426–2.995) <0.001
HbA1c (%) 5.72 ± 0.55 5.60 ± 0.40 5.70 ± 0.46 5.75 ± 0.58 5.89 ± 0.70 <0.001
Waist‑hip ratio 0.909 ± 0.287 0.867 ± 0.026 0.927 ± 0.026 0.882 ± 0.017 0.934 ± 0.026 <0.001
BMI (kg/m2) 24.7 ± 3.0 22.8 ± 2.1 26.0 ± 2.3 24.5 ± 1.9 27.1 ± 2.7 <0.001
Waist circumference (cm) 86.6 ± 7.9 81.6 ± 5.9 89.4 ± 6.1 86.7 ± 5.3 93.9 ± 7.1 <0.001
Lean mass (kg) 53.3 ± 5.8 52.0 ± 5.3a 52.2 ± 5.6a 54.4 ± 5.6 54.9 ± 6.1 <0.001
Fat mass (kg) 17.6 ± 6.0 13.7 ± 3.7 20.2 ± 4.7 17.0 ± 3.4 23.7 ± 5.8 <0.001
Percent body fat (%) 23.3 ± 5.3 19.7 ± 4.0 26.5 ± 3.8 22.7 ± 3.1 28.7 ± 4.0 <0.001
Proportion of subjects with  
diabetes (%)
1,264 (5.9) 229 (2.5) 130 (5.9) 303 (6.2) 602 (11.6) <0.001
Proportion of subjects with  
hypertension (%)
2,116 (9.9) 496 (5.5) 290 (13.1) 424 (8.7) 907 (17.4) <0.001
Proportion of subjects with  
statin medication (%)
767 (3.6) 171 (1.9) 102 (4.6) 205 (4.2) 289 (5.6) <0.001
Proportion of who has ever  
smoked (%)
12,122 (56.8) 4,853 (53.6) 2,825 (58.2) 1,573 (58.5) 6,571 (60.4) <0.001
Proportion of subjects with do 
regular exercise (%)
3,807 (17.8) 1,750 (19.3) 421 (19) 790 (16.3) 846 (16.3) <0.001
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Of the total subjects, 10,063 (47.2%) had NAFLD 
and 7,424 (34.8%) had abdominal obesity. The preva-
lence of NAFLD increased from 8,220 (45.8%) in sub-
jects with CACS = 0 to 1,503 (53.6%) in subjects with 
0  <  CACS  ≤  100 and 340 (58.3%) in subjects with 
CACS >100 (Figure  2). The prevalence of abdomi-
nal obesity increased from 5,738 (32%) in subjects 
with CACS  =  0 to 1,336 (47.7%) in subjects with 
0 < CACS ≤ 100 and 794 (60%) in subjects with CACS 
>100 (Figure 2).
Risk for coronary artery calcification in subjects with either 
NAFLD or abdominal obesity
In univariate analyses, the OR for CAC was much 
higher in the abdominal obesity group than in the 
NAFLD group. Whereas in the age adjusted model, 
the odds ratio (OR) of CAC in subjects with NAFLD 
increased compared with those without NAFLD 
(Table  3). OR for CAC was higher in subjects with 
abdominal obesity compared with those without 
abdominal obesity (Table 3).
In multivariable analyses, after adjustment for age, dia-
betes history, hypertension, cigarette smoking, and phys-
ical inactivity, the OR of the NAFLD group attenuated, 
but the NAFLD group showed a relatively increased risk 
for CAC compared to those without NAFLD, and the OR 
was higher than that in subjects with abdominal obesity 
[1.360; 95% CI 1.253–1.476) vs. (1.220; 95% CI 1.122–
1.326)] (Table  3). With additional adjustment for total 
cholesterol (TC), high-density lipoprotein cholesterol 
Table 2 Comparison of coronary artery calcium score among the four groups divided by non-alcoholic fatty liver disease 
and abdominal obesity status
NAFLD nonalcoholic fatty liver disease, CACS coronary artery calcium score.
a P value analyzed by one-way ANOVA.
b P value analyzed by ANCOVA.
c P value analyzed by Chi square test.




















Mean Ln (CACS + 1) 0.49 ± 1.28 0.34 ± 1.05 0.77 ± 1.60 0.40 ± 1.16 0.72 ± 1.53 <0.001a
Age‑adjusted mean Ln (CACS + 1) – 0.416 ± 0.013d 0.490 ± 0.026d 0.488 ± 0.017d 0.624 ± 0.017 <0.001b
Number of subjects with CACS = 0 (%) 17,950 (84.1) 8,025 (88.7) 1,705 (76.8) 4,187 (86.2) 4,033 (77.5) <0.001c
Number of subjects with CACS >0 (%) 3,385 (15.9) 1,027 (11.3) 515 (23.2) 672 (13.8) 1,171 (22.5) <0.001c
Figure 1 Age‑adjusted means of coronary artery calcium score among the four groups. *,†No differences between the groups with same footnotes 
in post hoc analyses.
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(HDL-C) and HOMA-IR, subjects with NAFLD consist-
ently showed increased OR for CAC, whilst subjects with 
abdominal obesity showed non-significantly increased 
OR for CAC (Table 3).
Risk for coronary artery calcification in groups divided 
by NAFLD and abdominal obesity status
A formal analysis to compare the association of CAC 
with NAFLD or abdominal obesity is shown in Table 4. 
In univariate analyses, the OR of CAC was the high-
est in the group with abdominal obesity only, the sec-
ond highest in the group with both abnormalities, and 
the second lowest in the group with NAFLD only. In the 
age-adjusted model, the OR for CAC was the highest in 
the group with both abnormalities, and the NAFLD only 
group had a higher risk of CAC than the abdominal only 
group. Likewise, in multivariable analyses, the OR for 
CAC was the highest in the group with both abnormali-
ties (1.465; 95% CI 1.324–1.623). The NAFLD only group 
showed significantly increased OR for CAC compared 
to that in the abdominal obesity only group (1.286; 95% 
CI 1.151–1.436) vs. (OR  =  1.076; 95% CI 0.939–1.233) 
(Table  4). While the risk of CAC in the NAFLD only 
group attenuated but remained statistically significant, 
the abdominal obesity only group was not associated 
with CAC in models adjusted for age, history of diabetes, 
hypertension, cigarette smoking, and physical inactiv-
ity. Further adjustment for TC, HDL-C and HOMA-IR 
attenuated the OR with significantly increased OR for 
CAC only in subjects with both NAFLD and abdominal 
obesity (Table 4).
Discussion
In this study performed in a large health-screening male 
cohort, we found that subjects with NAFLD had a sig-
nificantly increased risk for CAC compared to that in 
men with abdominal obesity. While the CACS was the 
highest in subjects with abdominal obesity only and the 
lowest in subjects without either abnormality, the age-
adjusted mean of CACS was the highest in subjects with 
both abnormalities. In the post hoc analysis, the risk for 
CAC was the highest in subjects with both abnormalities, 
the subjects with NAFLD without abdominal obesity had 
a significantly increased risk for CAC, and the subjects 
with abdominal obesity without NAFLD were not sig-
nificantly associated with CAC. Our results indicate that 
Figure 2 Prevalence of NAFLD (a) and abdominal obesity (b) according to the CAC grade. NAFLD non‑alcoholic fatty liver disease, CAC coronary 
artery calcification.
Table 3 Odds ratio for coronary artery calcification in subjects with either NAFLD or abdominal obesity
Model 1 was adjusted for age.
Model 2 was adjusted for age, diabetes, hypertension, smoking and physical activity.
Model 3 was adjusted for age, diabetes, hypertension, smoking and physical activity, total cholesterol, HDL-C and HOMA-IR.
NAFLD non-alcoholic fatty liver disease, CACS coronary artery calcium score, OR odds ratio, CI confidence interval, HDL-L high-density lipoprotein cholesterol, HOMA-IA 
homeostasis model assessment-insulin resistance.
Independent 
variables
Coronary artery calcification (CACS >0)
N (%) Crude OR  
(95% CI)
p Model 1 OR  
(95% CI)
p Model 2 OR  
(95% CI)
p Model 3 OR  
(95% CI)
p
NAFLD 1,843 (54.4) 1.415 (1.314–1.524) <0.001 1.511 (1.395–1.637) <0.001 1.360 (1.253–1.476) <0.001 1.161 (1.061–1.271) <0.001
Abdominal 
obesity
1,686 (49.8) 2.112 (2.097–2.656) <0.001 1.346 (1.240–1.461) <0.001 1.220 (1.122–1.326) <0.001 1.005 (0.839–1.204) 0.954
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NAFLD is more closely associated with coronary artery 
calcification than abdominal obesity.
NAFLD refers to the accumulation of fat in more than 
5% of hepatocytes in subjects whose alcohol intake is 
lower than 20 g/d [6]. Although NAFLD is known as the 
hepatic manifestation of IR or metabolic syndrome, more 
recent reports have suggested that subjects with NAFLD 
are at increased risk for CAD independent of metabolic 
syndrome and insulin resistance [33, 34]. Many studies 
have reported increased risk for CAC in subjects with 
NAFLD [17–23]. Kim et al. reported that NAFLD is asso-
ciated with CAC independently of the traditional risk 
factors, including visceral adipose tissue [35]. Further 
researches suggest that not just NAFLD, but the presence 
of non-alcoholic steatohepatitis (NASH) or fibrosis is 
more associated with development of atherosclerosis [36, 
37]. Meanwhile, obesity has a variable association with 
CAC depending on the measures used for comparison 
[38]. The most recent reports indicate that when abdomi-
nal obesity is assessed using the WHR, it can be consid-
ered a strong risk factor for CAC [39–41]. Our research 
shows that abdominal obesity measured using the WHR 
was highly correlated with CAC across the body.
In this study, men with WHR greater than 0.9 and 
without NAFLD were older and had higher blood pres-
sure than men with NAFLD and without abdominal obe-
sity. Other studies have reported that the WHR is closely 
related to hypertension [42, 43]. Our results illustrate that 
CACS was highest in subjects with only abdominal obe-
sity. After adjusting for risk factors of CAD including age 
and metabolic parameters, NAFLD and abdominal obe-
sity showed a synergistically increased risk for subclinical 
atherosclerosis. In addition, subjects with NAFLD only 
retained a significantly higher risk for CAC than those 
with only abdominal obesity when other well-established 
risk factors were taken into account. One of the reasons 
for the higher risk for CAC in subjects with NAFLD 
only, could be due to the higher prevalence of diabetes 
in subjects with NAFLD only compared with those with 
abdominal obesity only, since, diabetes is a well-known 
cause for CAC [44]. However, the significantly increased 
risk for CAC was consistent even after adjustment for 
the presence of diabetes. Our result was in the opposite 
to the result from Coronary Artery Risk Development in 
Young Adults (CARDIA) Study performed in 2,424 par-
ticipants, in that the association of CAC and NAFLD was 
attenuated after additional adjustment for visceral adi-
posity, which suggest the importance of abdominal obe-
sity in association between CAC and NAFLD [20].
Fat accumulation in hepatocytes is more closely asso-
ciated with VAT [45]. Increased VAT plays a role in the 
pathogenesis of NAFLD due to the secretion of pro-
inflammatory cytokines and adipokines, and the release of 
free fatty acids into the portal system [46, 47]; thus visceral 
fat accumulation might be a mediator that links NAFLD 
to CAD [48]. A recent review and a study has shown that 
inflammation may be an underlying cause of CAD and 
also CAC [18, 49]. However, in our study, there was no 
significant difference in the inflammatory marker hs-CRP 
between the NAFLD only and abdominal obesity only 
groups. Several researchers have reported that abdominal 
obesity is consistently associated with NAFLD in 60–95% 
of the cases, and abdominal obesity assessed by WHR is 
closely related the occurrence of NAFLD [50]. This means 
that a high WHR, without evidence of NAFLD, may be 
limited as an independent risk factor for CAD.
The present study has some limitations. First, MDCT 
for CAC scoring was performed as part of a health 
checkup rather than for any specified research purpose, 
and there were no predetermined criteria for undergoing 
Table 4 Odds ratio for coronary artery calcification in groups divided by NAFLD and abdominal obesity status
Model 1 was adjusted for age.
Model 2 was adjusted for age, diabetes, hypertension, smoking and physical activity.
Model 3 was adjusted for age, diabetes, hypertension, smoking and physical activity, total cholesterol, HDL-C and HOMA-IR.
NAFLD non-alcoholic fatty liver disease, CACS coronary artery calcium score, OR odds ratio, CI confidence interval, HDL-L high-density lipoprotein cholesterol, HOMA-IA 
homeostasis model assessment-insulin resistance.
Coronary artery  
calcification
Crude OR  
(95% CI)
p Model 1 OR  
(95% CI)
p Model 2 OR  
(95% CI)
Model 3 OR  
(95% CI)
p
NAFLD (−), abdominal 
obesity (−)
Reference – 1.000 – 1.000 – 1.000 –
NAFLD (−), abdominal 
obesity (+)
2.360 (2.097–2.656) <0.001 1.181 (1.033–1.349) 0.015 1.076 (0.939–1.233) 0.277 0.974 (0.848–1.119) 0.708
NAFLD (+), abdominal 
obesity (−)
1.254 (1.130–1.392) <0.001 1.363 (1.221–1.521) <0.001 1.286 (1.151–1.436) <0.001 1.111 (0.990–1.247) 0.074
NAFLD (+), abdominal 
obesity (+)
2.269 (2.070–2.487) <0.001 1.694 (1.535–1.870) <0.001 1.465 (1.324–1.623) <0.001 1.190 (1.061–1.334) 0.003
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the test. Most of the examinees were employees and fam-
ily members of various industrial companies from around 
the country. Second, it has been reported that ultra-
sonography has high and variable sensitivity and cannot 
distinguish steatohepatitis from simple steatosis [51]. In 
addition, the failure to perform transient elastography 
is a major limitation in our study, since a recent study 
reported the independent association of hepatic fibrosis 
assessed by elastography with CACS [21]. Third, deter-
mination of alcohol intake solely by self-questionnaire 
might have caused bias. Lastly, the cross-sectional nature 
of the study design cannot contribute to clarifying how 
mechanistically NAFLD is associated with CAC.
Conclusion
In this large, health-screening population, CACS was sig-
nificantly higher in subjects with NAFLD than in those with 
abdominal obesity after adjusting for age, diabetes, hyper-
tension, smoking, and physical activity, including some of 
the components involved with metabolic syndrome. Very 
little is known about the exact role of NAFLD as a risk 
factor for CAD. However, it is clear that the prevalence of 
NAFLD has greatly increased in recent years, and that of 
CAD has increased even in subjects without abdominal 
obesity. Therefore, it is important to find the underlying 
pathogenesis that links NAFLD to CAD, and to identify the 
necessary management to prevent and reduce the causes of 
these two diseases. In the future diagnosis of NAFLD, par-
ticular attention should be focused on men who are most 
likely to benefit from intensive lifestyle modification and 
pharmacological treatment to decrease CAD risk.
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